Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

PD-MitoQUANT

Financiado

PD MitoQUANT A quantitative approach towards the characterisation of mitochond...

PD MitoQUANT A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson s disease Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is lacking. Through provision of quantitative and systematic characterisation of mitochondria... ver más

31/07/2022

ROYAL COLLEGE OF S...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 16 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-07-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

IMI2-2017-13-04: Mitochondrial Dysfunction in Neurodegeneration

I+D

Cerrada hace 6 años

0% 65% 100%

16 Participantes

ROYAL COLLEGE OF SURGEONS IN...

1.09M€ | Lider

VALORA CONSULTORES DE GESTIO...

306.75K€ | Participante

GENEXPLAIN

147.92K€ | Participante

UNIVERSITY COLLEGE LONDON

358.28K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 41 meses Fecha Inicio: 2019-02-19
Fecha Fin: 2022-07-31

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND

TRL 4-5

Presupuesto del proyecto 7M€

Descripción del proyecto Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is lacking. Through provision of quantitative and systematic characterisation of mitochondrial dysfunction, PD-MitoQUANT will provide unprecedented understanding of the role of mitochondrial dysfunction in PD, identify and validate novel disease biomarkers, and propose innovative therapeutic targets that can be further progressed by the EFPIA partners. The consortium leverages multi-disciplinary expertise in the fields of αSyn biochemistry, iPSC-derived PD models, mitochondrial function and structural analysis, proteotoxicity, ER stress and UPR signaling, systems biology of mitochondrial function, and in vivo animal models. A key focus will be quantitative description and integrated analysis of mitochondrial function and its relation to proteotoxicity; representing a key panel of consortium partners Prehn [RCSI], Abramov [UCL], Corti [ICM] and Koopmann [RUMC] who also have assembled long–standing expertise in primary neuron culture, iPSC-derived neurons, PD in vivo models, proteostasis and ageing studies. These investigations will be supported by expert teams in iPSC-derived in vitro PD models and in vivo PD models from the academic partners (Hunot [ICM], Melki [CNRS], Di Monte [DZNE], Broccoli [CNR], SME [Mimetas] and EFPIA partners [Teva], [Lundbeck] and [UCB]. Through integrated in vitro, in silico and in vivo approaches, and supported computationally by SME [GENEXPLAIN], PD-MitoQUANT will perform thorough and unprecedented investigations of mitochondrial dysfunction. Finally, the consortium will initiate a European research platform of excellence investigating mitochondrial dysfunction in PD continuing beyond the project, further supported by [PUK]’s PD human tissue biobank. This will provide long-term and sustainable progress in the understanding of mitochondrial dysfunction in PD and towards clinical application.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores